title: Improved treatment for primary HIV infection by interferon-alfa therapy? Does HCV treatment in HIV/HCV coinfected patients help us to test this hypothesis? Reply to zur Wiesch and van Lunzen.
authors.affiliation: HIV-1 Immunopathogenesis Laboratory, Wistar Institute, Philadelphia, Pennsylvania.
authors.forename: Livio
authors.initials: L
authors.lastname: Azzoni
authors.forename: Andrea S
authors.initials: AS
authors.lastname: Foulkes
authors.forename: Emmanouil
authors.initials: E
authors.lastname: Papasavvas
authors.forename: Angela M
authors.initials: AM
authors.lastname: Mexas
authors.forename: Kenneth M
authors.initials: KM
authors.lastname: Lynn
authors.forename: Karam
authors.initials: K
authors.lastname: Mounzer
authors.forename: Pablo
authors.initials: P
authors.lastname: Tebas
authors.forename: Jeffrey M
authors.initials: JM
authors.lastname: Jacobson
authors.forename: Ian
authors.initials: I
authors.lastname: Frank
authors.forename: Una
authors.initials: U
authors.lastname: O'Doherty
authors.forename: Jay
authors.initials: J
authors.lastname: Kostman
authors.forename: Luis J
authors.initials: LJ
authors.lastname: Montaner
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D016662:Virus Integration / Q000187:drug effects*; D014779:Virus Replication / Q000187:drug effects*
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D011092:Polyethylene Glycols